Abeona Therapeutics (ABEO) Change in Accured Expenses (2011 - 2026)

Abeona Therapeutics' Change in Accured Expenses history runs 11 years deep, the most recent figure standing at -$7.3 million for Q1 2026.

• On a quarterly basis, Change in Accured Expenses fell 207.61% year-over-year to -$7.3 million in Q1 2026; TTM through Mar 2026 was -$5.0 million, a 647.32% decrease from a year earlier, with the FY2025 full-year figure at -$85000.0, down 631.25% from the prior year.
• Change in Accured Expenses eased to -$7.3 million in Q1 2026 per ABEO's latest filing, from -$23000.0 in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $4.8 million in Q4 2022 and bottomed at -$7.3 million in Q1 2026.
• The 5-year median for Change in Accured Expenses is $1000.0 (2023), against an average of -$375666.7.
• Across the five-year window, Change in Accured Expenses surged 152.81% in 2023 and plunged 169100.0% in 2024, its largest moves.
• Year by year, Change in Accured Expenses stood at $4.8 million in 2022, then tumbled by 73.54% to $1.3 million in 2023, then plunged by 83.11% to $216000.0 in 2024, then tumbled by 110.65% to -$23000.0 in 2025, then tumbled by 31704.35% to -$7.3 million in 2026.
• Per Business Quant, the three latest ABEO Change in Accured Expenses figures stand at -$7.3 million (Q1 2026), -$23000.0 (Q4 2025), and $2.3 million (Q2 2025).